Alumis Inc. (ALMS) stock
Close on Nov 12, 2026Market cap $793.44MP/E –Yield –
Alumis Inc. reported revenue of $7.24M for the twelve months to Sep 30, 2026. Free cash flow was -$320.93M. At the latest close the market valued the company at $793.44M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $793.44M
- P/E ratio
- –
- Price to sales
- 109.61
- Price to book
- 2.10
- Dividend yield
- –
- Free cash flow yield
- -40.45%
Fundamentals
- Revenue
- $7.24M
- Net income
- -$423.09M
- EPS, diluted
- -$3.47
- Free cash flow
- -$320.93M
- Book value per share
- $2.93
- Diluted shares
- 129M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $6.62
- Open
- $6.50
- Day's range
- $6.13 – $6.61
- Volume
- 1,864,093
- Average volume (20 days)
- 1,844,219
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- -1.08
- 52-week range
- $4.60 – $31.35
- RSI (14 days)
- 38.6
- Volatility (1 year)
- 137.0%
- Relative volume
- 0.81×
- WACC
- 7.4%
On 2 of our idea lists: More cash than they're worth, Insiders buying the dip
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALMS | S&P 500 | Difference | ALMS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.2% | -2.7% | −10.5 pts | ||
| 3 months | -76.0% | -1.7% | −74.3 pts | ||
| Year to date | -37.2% | +11.9% | −49.1 pts | ||
| 1 year | +17.0% | +12.0% | +5.0 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alumis filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- News
- News
- Results
About Alumis
Pharmaceutical Preparations
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oral therapies to replace broad immunosuppression for patients with immune-mediated conditions. The company's lead product candidate is envudeucitinib, an allosteric Tyrosine Kinase 2 (TYK2) inhibitor being evaluated for plaque psoriasis and systemic lupus erythematosus. Its pipeline also includes A-005, a central nervous system-penetrant TYK2 inhibitor aimed at neuroinflammatory and neurodegenerative disorders, alongside lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease acquired via its merger with ACELYRIN.
Company profile, executives and historyAlumis stock: common questions
What is Alumis's stock price?
ALMS closed at $6.13 on Nov 12, 2026, down 7.40% on the day. Over the past 52 weeks it traded between $4.60 and $31.35.
What is Alumis's market cap?
Alumis was worth $793.44M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ALMS's P/E ratio?
Alumis lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.47), so it has no meaningful P/E ratio.
How much revenue does Alumis make?
Alumis reported revenue of $7.24M for the twelve months to Sep 30, 2026.
Does Alumis pay a dividend?
No. Alumis has not paid a cash dividend over the last twelve months.
When does Alumis report earnings next?
Alumis is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ALMS stock performed over the past year?
Including dividends, ALMS returned +17.0% over the past year, against +12.0% for the S&P 500.
How many ALMS shares are sold short?
11M shares were sold short at the latest FINRA report, 12.27% of the float, or 5.8 days of average trading volume.
Who are Alumis's competitors?
Companies most similar to Alumis by business, industry and size include ACRS, ZBIO, RANI, TVRD, PRAX.
See a number that looks wrong?